Abiopharma

🔍 Bell Michael Brian (Executive)

Company: Guardant Health, Inc. (GH)

Report Date: 2026-01-01

Detailed Transactions and Holdings:

• Acquired 10,520 shares of Common Stock (Direct)
  Date: 2026-01-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 40,185.00 | transaction_form_type: 4
• Acquired 3,324 shares of Common Stock (Direct)
  Date: 2026-01-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 43,509.00 | transaction_form_type: 4
• Acquired 7,110 shares of Common Stock (Direct)
  Date: 2026-01-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 50,619.00 | transaction_form_type: 4
• Acquired 2,084 shares of Common Stock (Direct)
  Date: 2026-01-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 52,703.00 | transaction_form_type: 4
• Sold 12,479 shares of Common Stock at $102.14 per share (Direct)
  Date: 2026-01-01 | Code: F | equity_swap_involved: 0 | shares_owned_after: 40,224.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 10,520 shares of Performance-Based Restricted Stock Units (Derivative)
  Date: 2026-01-01 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2, F3
• Sold 3,324 shares of Restricted Stock Units (Derivative)
  Date: 2026-01-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 23,268.00 | transaction_form_type: 4 | Footnotes: F4, F3
• Sold 7,110 shares of Performance-Based Restricted Stock Units (Derivative)
  Date: 2026-01-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 7,110.00 | transaction_form_type: 4 | Footnotes: F5, F3
• Sold 2,084 shares of Restricted Stock Units (Derivative)
  Date: 2026-01-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 6,253.00 | transaction_form_type: 4 | Footnotes: F6, F3
• Holds 10,520 shares of Performance-Based Restricted Stock Units (Derivative)
  Date: 2026-01-01 | Code: H | shares_owned_after: 10,520.00 | Footnotes: F2, F3

Footnotes:

• F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability.
• F2: This represents a performance-based restricted stock unit award granted on June 7, 2023, with a performance metric and 2-year vest period that was achieved. The shares vested on January 1, 2026.
• F3: Not applicable for Restricted Stock Units.
• F4: This represents a restricted stock unit award granted on November 8, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
• F5: This represents a performance-based restricted stock unit award granted on February 26, 2024, that a performance metric was achieved and that 33% of the shares subject to such award vested on March 1, 2025. 33% of the shares subject to the award vested on January 1, 2026, and the remaining 34% of the shares subject to the award will vest on January 1, 2027.
• F6: This represents a restricted stock unit award granted on December 13, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2024 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.